File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells
  • Basic View
  • Metadata View
  • XML View
TitleInhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells
 
AuthorsLi, RWS1
Seto, SW1
Au, ALS1
Kwan, YW1
Chan, SW3
Lee, SMY2
Tse, CM4
Leung, GPH1
 
KeywordsAdenosine transport
Smooth muscle cell
Sulindac
 
Issue Date2009
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar
 
CitationEuropean Journal Of Pharmacology, 2009, v. 612 n. 1-3, p. 15-20 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ejphar.2009.04.017
 
AbstractIt is generally accepted that the clinical efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) arises mainly from the inhibition of cyclooxygenase (COX). However, more evidence has suggested that certain pharmacological actions of NSAIDs may be mediated by COX-independent mechanisms. The present study investigated the effects of NSAIDs on adenosine uptake in human aortic smooth muscle cells (HASMCs). Among the NSAIDs tested (all at 100 μM), aspirin, ibuprofen and naproxen had no effect on [ 3H]adenosine uptake. Piroxicam inhibited [ 3H]adenosine uptake by 30%, while etodolac, indomethacin, ketoprofen, mefenamic acid and sulindac inhibited [ 3H]adenosine by 13-18%. Sulindac sulfide, an active metabolite of sulindac, inhibited [ 3H]adenosine uptake and [ 3H]nitrobenzylmercaptopurine ribonucleoside (NBMPR) binding of HASMCs with IC 50 values of 40.67 ± 4.82 and 24.19 ± 3.76 μM, respectively. Kinetic studies revealed that sulindac sulfide was a competitive inhibitor of adenosine uptake. Using the nucleoside-transporter-deficient PK15NTD cells that stably express equilibrative nucleoside transport (ENT) 1 and ENT2, it was found that the inhibitory effect of sulindac sulfide on ENT1 was greater than that on ENT2. Sulindac sulfide increased the extracellular adenosine level. In addition, it inhibited the proliferation of HASMCs and this anti-proliferative effect could be abolished by adenosine A 2B receptor antagonist. Our results suggest that sulindac sulfide may exert pharmacological effects through the inhibition of adenosine uptake, which modulates the availability of adenosine in the vicinity of adenosine receptors. © 2009 Elsevier B.V. All rights reserved.
 
ISSN0014-2999
2013 Impact Factor: 2.684
2013 SCImago Journal Rankings: 1.067
 
DOIhttp://dx.doi.org/10.1016/j.ejphar.2009.04.017
 
ISI Accession Number IDWOS:000267150900003
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLi, RWS
 
dc.contributor.authorSeto, SW
 
dc.contributor.authorAu, ALS
 
dc.contributor.authorKwan, YW
 
dc.contributor.authorChan, SW
 
dc.contributor.authorLee, SMY
 
dc.contributor.authorTse, CM
 
dc.contributor.authorLeung, GPH
 
dc.date.accessioned2010-05-31T03:52:30Z
 
dc.date.available2010-05-31T03:52:30Z
 
dc.date.issued2009
 
dc.description.abstractIt is generally accepted that the clinical efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) arises mainly from the inhibition of cyclooxygenase (COX). However, more evidence has suggested that certain pharmacological actions of NSAIDs may be mediated by COX-independent mechanisms. The present study investigated the effects of NSAIDs on adenosine uptake in human aortic smooth muscle cells (HASMCs). Among the NSAIDs tested (all at 100 μM), aspirin, ibuprofen and naproxen had no effect on [ 3H]adenosine uptake. Piroxicam inhibited [ 3H]adenosine uptake by 30%, while etodolac, indomethacin, ketoprofen, mefenamic acid and sulindac inhibited [ 3H]adenosine by 13-18%. Sulindac sulfide, an active metabolite of sulindac, inhibited [ 3H]adenosine uptake and [ 3H]nitrobenzylmercaptopurine ribonucleoside (NBMPR) binding of HASMCs with IC 50 values of 40.67 ± 4.82 and 24.19 ± 3.76 μM, respectively. Kinetic studies revealed that sulindac sulfide was a competitive inhibitor of adenosine uptake. Using the nucleoside-transporter-deficient PK15NTD cells that stably express equilibrative nucleoside transport (ENT) 1 and ENT2, it was found that the inhibitory effect of sulindac sulfide on ENT1 was greater than that on ENT2. Sulindac sulfide increased the extracellular adenosine level. In addition, it inhibited the proliferation of HASMCs and this anti-proliferative effect could be abolished by adenosine A 2B receptor antagonist. Our results suggest that sulindac sulfide may exert pharmacological effects through the inhibition of adenosine uptake, which modulates the availability of adenosine in the vicinity of adenosine receptors. © 2009 Elsevier B.V. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationEuropean Journal Of Pharmacology, 2009, v. 612 n. 1-3, p. 15-20 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ejphar.2009.04.017
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.ejphar.2009.04.017
 
dc.identifier.epage20
 
dc.identifier.hkuros157519
 
dc.identifier.isiWOS:000267150900003
 
dc.identifier.issn0014-2999
2013 Impact Factor: 2.684
2013 SCImago Journal Rankings: 1.067
 
dc.identifier.issue1-3
 
dc.identifier.openurl
 
dc.identifier.pmid19379728
 
dc.identifier.scopuseid_2-s2.0-65549129242
 
dc.identifier.spage15
 
dc.identifier.urihttp://hdl.handle.net/10722/59548
 
dc.identifier.volume612
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofEuropean Journal of Pharmacology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsEuropean Journal of Pharmacology. Copyright © Elsevier BV.
 
dc.subjectAdenosine transport
 
dc.subjectSmooth muscle cell
 
dc.subjectSulindac
 
dc.titleInhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Li, RWS</contributor.author>
<contributor.author>Seto, SW</contributor.author>
<contributor.author>Au, ALS</contributor.author>
<contributor.author>Kwan, YW</contributor.author>
<contributor.author>Chan, SW</contributor.author>
<contributor.author>Lee, SMY</contributor.author>
<contributor.author>Tse, CM</contributor.author>
<contributor.author>Leung, GPH</contributor.author>
<date.accessioned>2010-05-31T03:52:30Z</date.accessioned>
<date.available>2010-05-31T03:52:30Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>European Journal Of Pharmacology, 2009, v. 612 n. 1-3, p. 15-20</identifier.citation>
<identifier.issn>0014-2999</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/59548</identifier.uri>
<description.abstract>It is generally accepted that the clinical efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) arises mainly from the inhibition of cyclooxygenase (COX). However, more evidence has suggested that certain pharmacological actions of NSAIDs may be mediated by COX-independent mechanisms. The present study investigated the effects of NSAIDs on adenosine uptake in human aortic smooth muscle cells (HASMCs). Among the NSAIDs tested (all at 100&#160;&#956;M), aspirin, ibuprofen and naproxen had no effect on [ 3H]adenosine uptake. Piroxicam inhibited [ 3H]adenosine uptake by 30%, while etodolac, indomethacin, ketoprofen, mefenamic acid and sulindac inhibited [ 3H]adenosine by 13-18%. Sulindac sulfide, an active metabolite of sulindac, inhibited [ 3H]adenosine uptake and [ 3H]nitrobenzylmercaptopurine ribonucleoside (NBMPR) binding of HASMCs with IC 50 values of 40.67 &#177; 4.82 and 24.19 &#177; 3.76&#160;&#956;M, respectively. Kinetic studies revealed that sulindac sulfide was a competitive inhibitor of adenosine uptake. Using the nucleoside-transporter-deficient PK15NTD cells that stably express equilibrative nucleoside transport (ENT) 1 and ENT2, it was found that the inhibitory effect of sulindac sulfide on ENT1 was greater than that on ENT2. Sulindac sulfide increased the extracellular adenosine level. In addition, it inhibited the proliferation of HASMCs and this anti-proliferative effect could be abolished by adenosine A 2B receptor antagonist. Our results suggest that sulindac sulfide may exert pharmacological effects through the inhibition of adenosine uptake, which modulates the availability of adenosine in the vicinity of adenosine receptors. &#169; 2009 Elsevier B.V. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/ejphar</publisher>
<relation.ispartof>European Journal of Pharmacology</relation.ispartof>
<rights>European Journal of Pharmacology. Copyright &#169; Elsevier BV.</rights>
<subject>Adenosine transport</subject>
<subject>Smooth muscle cell</subject>
<subject>Sulindac</subject>
<title>Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0014-2999&amp;volume=612&amp;spage=15&amp;epage=20&amp;date=2009&amp;atitle=Inhibitory+effect+of+nonsteroidal+anti-inflammatory+drugs+on+adenosine+transport+in+vascular+smooth+muscle+cells</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.ejphar.2009.04.017</identifier.doi>
<identifier.pmid>19379728</identifier.pmid>
<identifier.scopus>eid_2-s2.0-65549129242</identifier.scopus>
<identifier.hkuros>157519</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-65549129242&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>612</identifier.volume>
<identifier.issue>1-3</identifier.issue>
<identifier.spage>15</identifier.spage>
<identifier.epage>20</identifier.epage>
<identifier.isi>WOS:000267150900003</identifier.isi>
<publisher.place>Netherlands</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. University of Macau
  3. Hong Kong Polytechnic University
  4. The Johns Hopkins School of Medicine